Trial Profile
A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Halobetasol/Lidocaine (Primary) ; Lidocaine; Ulobetasol
- Indications Haemorrhoids
- Focus Therapeutic Use
- Sponsors Citius Pharmaceuticals Inc
- 02 Jan 2024 According to a Citius Pharmaceuticals media release, in early 2024, the company plans to meet with the FDA to discuss the results of the trial and next steps in the Halo-Lido program.
- 14 Aug 2023 According to a Citius Pharmaceuticals media release, company expecting research and development expenses will stabilize in fiscal 2023 as focus is on the commercialization of LYMPHIR and complete Phase 3 trial for Mino-Lok and Phase 2b trial for Halo-Lido.
- 14 Aug 2023 According to a Citius Pharmaceuticals Inc media release, R&D expenses were $3.8 million and $11.9 million for the three and nine months ended June 30, 2023, respectively, compared to $4.9 million and $13.8 million for the comparable periods ended June 30, 2022. The decrease reflects lower Mino-Lok and LYMPHIR trial costs offset by higher Halo-Lido Phase 2b study costs as the trial was completed during the three months ended June 30, 2023.